June 21, 2018

Chasing the Next Biotech Unicorn

How private equity sets to thrive in the biotech boom in Hong Kong

New listing rules in Hong Kong for biotech and the healthcare reform in China are propelling capital raising activities in the region. Rocketed valuation in the biotech sector drives interest from private equity investments, who demand swift investment cycle with a clear profit-making path for going public. The importance of rigorous and timely pre-investment screening and due diligence process is at an all-time high.

Download this whitepaper to examine the potential opportunities and headwinds in the biotech state-of-play, as well as factors that would drive deal success.

Fill out the form to download this whitepaper.

You may also like:

Datasite Forecaster January Global Outlook

Check out this month's Forecaster, where we provide a quick update on where the M&A market is heading, based on aggregated and anonymized data room activity.

969013854
Deal Drivers: APAC 2023 Outlook

In 2022, M&A volume across the APAC region showed unwavering strength through the first nine months of the year. Deal volume has been defiantly buoyant, remaining well above historic levels through the first three quarters of the year even as economic growth slowed. But with economic headwinds continuing to build across the region, will M&A bounce back in 2023?

Datasite Forecaster December Global Outlook

Check out this month's Forecaster, where we provide a quick update on where the M&A market is heading, based on aggregated and anonymized data room activity.

M&A Professional